APVO - CIK 0001671584
Aptevo Therapeutics Inc. trades as APVO. In its fiscal 2022 annual report the company posted revenue of $3.11M, down 74.7% from the prior year and net income of -$25.97M. This page tracks Aptevo Therapeutics Inc. through 690 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years Aptevo Therapeutics Inc.'s revenue declined from $33.60M to $3.11M, a compound annual decline rate of 28.8%. Net profit margin expanded from -1125.8% to 257.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-27 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-05-06 |
| Annual report | 10-K | 2026-03-26 |
| Major company event | 8-K | 2026-03-26 |
| Major company event | 8-K | 2026-03-11 |
| Major company event | 8-K | 2026-02-19 |
The largest companies sharing Aptevo Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Aptevo Therapeutics Inc. reported revenue of $3.11M for fiscal year 2022, a decrease of 74.7% year over year.
In its latest fiscal year Aptevo Therapeutics Inc. reported a net loss of $25.97M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.